Block & Leviton LLP is investigating Candel Therapeutics for potentially misleading investors about the readiness of its FDA application for aglatimagene, a prostate cancer drug. The company had claimed manufacturing and submission timelines were on track for late 2026 but later delayed the FDA application to mid-2027 due to assay issues. This discrepancy coincided with a $50 million stock sale and a 39% drop in share price. Investors who suffered losses may be eligible to seek recovery through legal action initiated by Block & Leviton.
Candel Therapeutics is under investigation for securities fraud, with a notable 39% share price drop following delayed FDA application timelines. For readers following the health sector, here is Pluang's market snapshot as of Nov 14, 2026 00:01 WIB: out of 150 priced US health stocks, 50 rose and 100 fell. Key movers include CTXR at USD 0.51 with a 4.21% decline and 84% sell order activity, RXRX at USD 3.21 down 3.75%, and TVTX at USD 49.70 down 3.61%.
Susan R. Burns, Ph.D., President of the University of Mount Saint Vincent, has been awarded the 2027 Courageous Leadership Award for her visionary and bold leadership. Since 2021, she has led the university through significant transformation, includi...
Solo, a company specializing in privacy-preserving human verification, has integrated its SDK into JellyJelly, a social video app co-founded by Venmo's co-founder. This integration ensures that every JellyJelly account belongs to a real, unique perso...
The U.S. market for AI-enabled ophthalmic diagnostic devices is projected to grow from $72.5 million in 2026 to $267.2 million by 2033, expanding at a 20.5% CAGR. Growth is driven by rising diabetes-related eye diseases, FDA clearances for autonomous...
The global medical display monitors market, valued at $2.8 billion in 2025, is projected to grow to $4.0 billion by 2033 with a CAGR of 4.6%. Growth is fueled by rising adoption of digital imaging systems, demand for accurate diagnostics, and healthc...
Oppenheimer downgraded Enovix from Outperform to Perform as the company expands production in South Korea and shifts focus to drone and smart-eyewear customers. Enovix reported a 38% revenue increase to $11 million in Q3 but saw its adjusted loss wid...
